Silence Therapeutics
Stage
PIPE | IPOMarket Cap
0.52BStock Price
13.55About Silence Therapeutics
Silence Therapeutics (LON: SLN) focuses on the development of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.
Loading...
Loading...
Silence Therapeutics Patents
Silence Therapeutics has filed 59 patents.
The 3 most popular patent topics include:
- molecular biology
- rna
- gene expression
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/25/2022 | 11/21/2023 | Molecular biology, Catalysis, Amino acids, Proteins, Chemical processes | Grant |
Application Date | 7/25/2022 |
|---|---|
Grant Date | 11/21/2023 |
Title | |
Related Topics | Molecular biology, Catalysis, Amino acids, Proteins, Chemical processes |
Status | Grant |
Latest Silence Therapeutics News
Dec 1, 2023
(marketscreener.com) Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer 1 December 2023 LONDON, Silence Therapeutics plc, Nasdaq: SLN , an experienced and innovative biotechnology company committed to transforming people's lives by...https://www.marketscreener.com/quote/stock/SILENCE-THERAPEUTICS-PLC-111895683/news/Silence-Therapeutics-Curtis-Rambaran-MD-promoted-to-Chief-Medical-Officer-Marie-Wikstrom-Lindhol-45482562/?utm_medium=RSS&utm_content=20231201
Silence Therapeutics Frequently Asked Questions (FAQ)
Where is Silence Therapeutics's headquarters?
Silence Therapeutics's headquarters is located at 72 Hammersmith Road, London.
What is Silence Therapeutics's latest funding round?
Silence Therapeutics's latest funding round is PIPE.
Who are the investors of Silence Therapeutics?
Investors of Silence Therapeutics include Deep Track Capital and Mallinckrodt.
Who are Silence Therapeutics's competitors?
Competitors of Silence Therapeutics include Ionis Pharmaceuticals.
Loading...
Compare Silence Therapeutics to Competitors
Dicerna Pharmaceuticals is a biopharmaceutical company that operates in the healthcare sector. The company focuses on the development of medicines using ribonucleic acid interference (RNAi) technology to silence or turn off the genes that cause or contribute to diseases. These therapies are aimed at both rare and common diseases. It was founded in 2007 and is based in Watertown, Massachusetts.
Akcea Therapeutics is a company focused on the discovery, development, and delivery of genetic medicines, operating in the pharmaceutical industry. The company's main offerings include the development of RNA-targeted therapeutics designed to treat both rare diseases and conditions affecting millions of people. The company primarily serves the healthcare sector. It is based in Cambridge, Massachusetts.
Sarepta Therapeutics is a global biotechnology company that operates in the biopharmaceutical sector, focusing on rare diseases. The company's main services include the development of precision genetic medicines, utilizing platforms such as gene therapy, RNA technologies, and gene editing to treat diseases that impact neuromuscular and central nervous system functions. Sarepta Therapeutics primarily serves the healthcare industry, specifically targeting sectors dealing with rare neuromuscular and central nervous system diseases. It was founded in 1980 and is based in Cambridge, Massachusetts.
Alnylam Pharmaceuticals is a leading company focused on RNA interference (RNAi) therapeutics within the pharmaceutical industry. The company's main offerings include the development of innovative medicines to treat rare genetic, cardio-metabolic, acute hepatic infectious, and central nervous system (CNS) and ocular diseases. These medicines work by using RNAi to 'silence' or turn off specific genes that cause or contribute to disease. It was founded in 2002 and is based in Cambridge, Massachusetts.
WAVE Life Sciences is a genetic medicines company operating in the healthcare sector. The company focuses on the development of treatments for genetically defined diseases, using its proprietary discovery and drug development platform, PRISM, to design, optimize, and produce novel, stereopure oligonucleotides. These potential medicines aim to reduce, restore, or modulate proteins responsible for genetic diseases. It was founded in 2012 and is based in Cambridge, Massachusetts.
Moderna (NASDAQ: MRNA) focuses on drug discovery and drug development based on messenger ribonucleic acid (mRNA). The company's main service is the creation of a new generation of transformative medicines that use mRNA to prompt the immune system to create tools to treat or prevent diseases. Moderna primarily sells to the healthcare industry. It was founded in 2010 and is based in Cambridge, Massachusetts.
Loading...